AXELROD SYMPOSIUM PROTEIN KINASES IN TUNE - SPECIAL SECTION
G-Protein Coupled Receptor Signaling and Mammalian Target of Rapamycin Complex 1 Regulation
Chase H. Melick, Tshering D. Lama-Sherpa, Adna Curukovic, and Jenna L. Jewell

Degraders: The Ultimate Weapon Against Amplified Driver Kinases in Cancer
Pedro Torres-Ayuso and John Brognard

CCT and CCT-Like Modular Protein Interaction Domains in WNK Signaling
Clinton A. Taylor IV and Melanie H. Cobb

mTOR Regulation of AGC Kinases: New Twist to an Old Tail
Timothy R. Baffi and Alexandra C. Newton

The Tails of Protein Kinase A
Susan S. Taylor, Kristoffer Søberg, Evan Kobori, Jian Wu, Sabine Pautz, Friedrich W. Herberg, and Bjørn Steen Skålhegg

ARTICLES

A Recombinant Dimethylarginine Dimethylaminohydrolase-1–Based Biotherapeutics to Pharmacologically Lower Asymmetric Dimethyl Arginine, thus Improving Postischemic Cardiac Function and Cardiomyocyte Mitochondrial Activity
Young Lee, Jaipal Singh, Susan R. Scott, Bradley Ellis, Pinar Zorlutuna, and Meijing Wang

A High-Throughput Screening Assay to Identify Drugs that Can Treat Long QT Syndrome Caused by Trafficking-Deficient Kv11.1 (hERG) Variants
Christian L. Egly, Daniel J. Blackwell, Jeffrey Schmeckpeper, Brian P. Delisle, C. David Weaver, and Björn C. Knollmann

Multipathway In Vitro Pharmacological Characterization of Specialized Proresolving G Protein-Coupled Receptors
Jon Merlin, Julia Park, Teresa H. Vandekolk, Stewart A. Fabb, Jeannine Allinne, Roger J. Summers, Christopher J. Langmead, and Darren M. Riddy

Yeast β-glucan Increases Etoposide Sensitivity in Lung Cancer Cell Line A549 by Suppressing Nuclear Factor Erythroid 2-Related Factor 2 via the Noncanonical Nuclear Factor Kappa B Pathway
Ferbian Milas Siswanto, Akiyoshi Tamura, Rika Sakuma, and Susumu Imaoka

ERRATUM
Correction to “ Activation of the Orphan G Protein–Coupled Receptor GPR27 by Surrogate Ligands Promotes β-Arrestin 2 Recruitment”

Supplemental material is available online at http://molpharm.aspetjournals.org.

About the cover: Concentration-response curves of the FPR2/AKX agonists. See the article by Merlin et al. (dx.doi.org/10.1124/molpharm.121.000422).